Is there a standard strategy in the management of locally advanced non-small cell lung cancer?

Lung Cancer

Volumn 34, Issue SUPPL. 4, 2001, Pages 9-14

  Novello, S ^a   Le Chevalier, T ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

Chemotherapy; Non small cell lung cancer; Radiotherapy

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; DOCETAXEL; ETOPOSIDE; GEMCITABINE; MITOMYCIN; NAVELBINE; PACLITAXEL; RADIOSENSITIZING AGENT; TIRAPAZAMINE; VINBLASTINE; VINDESINE;

ADJUVANT CHEMOTHERAPY; BLOOD TOXICITY; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CONFERENCE PAPER; DRUG INDICATION; HUMAN; LUNG NON SMALL CELL CANCER; PATIENT CARE; PRIORITY JOURNAL; SURVIVAL RATE;

EID: 0035198967     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-5002(01)00399-3     Document Type: Conference Paper

References (35)

1. Impact of irradiation technique and tumor extent in tumor control and survival of patients with unresectable non-small-cell lung carcinoma: report by the Radiation Therapy Oncology Group
2. Results of high dose thoracic irradiation incorporatine beam's eye view display in non-small cell lung cancer: a retrospective multivariate analysis
3. Response toxicity failure patterns, and survival in five Radiation Therapy Oncology Group (RTOG) trials for sequential and/or concurrent chemotherapy and radiotherapy for locally advanced non-small-cell carcinoma of the lung
4. A randomized phase I/II trial of hyperfractionated radiation therapy with total doses of 60.0 Gy to 79.2 Gy: possible survival benefit with 69.6 Gy in favorable patients with Radiation Therapy Oncology Group 83-11
5. Continuous hyperfractionated accelerated radiotherapy (CHART) vs. conventional radiotherapy in non-small cell lung cancer: a randomized multicentre trial
6. Experience with dose escalation using CHARTWEL (continuous hyperfractionated accelerated radiotherapy weekend less) in non-small-cell lung cancer
7. High-dose hyperfractionated accelerated radiotherapy using a concurrent boost for the treatment of nonsmall cell lung cancer: unusual toxicity and promising early results
8. Dose escalation in non-small cell lung cancer (NSCLC) using conformal 3-dimensional radiation therapy (C3DRT): update of a phase I trial
9. Hyperfractionated radiation therapy with or without concurrent low-dose daily carboplatin/etoposide for stage III non-small-cell-lung cancer: a randomized study
10. Improved survival in stage III non-small-cell lung cancer: seven year follow-up of cancer and leukemia group B (CALGB) 8433 trial
11. Radiation Therapy Oncology Group (RTOG) 88-08 and Eastern Cooperative Oncology Group (ECOG) 4588: preliminary results of a phase III trial in regionally advanced unresectable non-small-cell lung cancer
12. ASTRO (American Society for Therapeutic Radiology and Oncology) plenary: effect of chemotherapy on locally advanced non-small cell lung carcinoma: a randomised study of 353 patients. GETCB (Groupe d'Etude et Traitement de Cancers Bronchiques), FNCLCC (Federation Nationale des Centres de Lutte contre le Cancer) and the CEBI trialists
13. Significant effect of adjuvant chemotherapy on survival in locally advanced non-small-cell carcinoma
14. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomized clinical trials
15. Randomized trails of radiotherapy alone versus combined chemotherapy and radiotherapy in stages IIIA and IIIB non-small cell lung cancer. A meta-analysis
16. Chemotherapy plus radiotherapy compared with radiotherapy alone in the treatment of locally advanced unresectable non-small cell lung cancer. A meta-analysis
17. Effects of concomitant cisplatin and radiotherapy on inoperable non-small cell lung cancer
18. Randomized trial of hyperfractionated radiation therapy with or without concurrent chemotherapy for stage III non-small cell lung cancer
19. Concurrent chemoradiation therapy with oral etoposide and cisplatin for locally advanced inoperable non-small cell lung cancer: Radiation Therapy Oncology Group Protocol 91-06
20. Phase II study of concurrent radiotherapy and chemotherapy for unresectable stage III non-small-cell lung cancer
21. Phase II study of concurrent chemotherapy and radiotherapy for unresectable stage III non-small-cell lung cancer: long-term follow-up results. Japan Clinical Oncology Group Protocol 8902
22. A randomized phase III study of concurrent vs. sequential thoracic radiotherapy (TRT) in combination with mitomycin (M) vindesine (V) and cisplatin (P) in unresectable stage III non-small cell lung cancer (NSCLC): preliminary analysis
23. Phase III study of concurrent vs. sequential thoracic radiotherapy (TRT) in combination with Mitomycin (M) Vindesine (V) and Cisplatin (P) in unresectable stage III non-small cell lung cancer (NSCLC): five year median follow-up results
24. Phase III comparison of sequential vs. concurrent chemoradiation for patients (Pts) with unresected stage III non-small cell lung cancer (NSCLC): initial report of Radiation Therapy Oncology Group (RTOG) 9410
25. Radiosensitization with carboplatin for patients with unresectable stage III non-small cell lung cancer: a phase III trial of the Cancer Leukemia Group B and the Eastern Cooperative Oncology Group
26. Weekly paclitaxel/cisplatin with concurrent radiotherapy in patients with locally advanced non-small cell lung cancer: a phase I study
27. Phase II trial of weekly paclitaxel, carboplatin and simultaneous thoracic radiotherapy (TRT) for locally advanced non-small cell lung cancer (NSCLC)
28. Weekly paclitaxel and carboplatin with simultaneous thoracic radiotherapy (TRT) for locally advanced non-small cell lung cancer (NSCLC): three year follow-up
29. Concurrent paclitaxel carboplatin and radiation therapy for locally advanced non-small cell lung cancer
30. Induction platinum-based chemotherapy followed by radical hyperfractionated radiotherapy with concurrent chemotherapy in the treatment of locally advanced non-small cell lung carcinoma of the lung
31. A randomised phase II study of gemcitabine or paclitaxel or vinorelbine with cisplatin as induction chemotherapy (Ind CT) and concomitant chemoradiotherapy (XRT) for unresectable stage III non-small cell lung cancer (NSCLC) (CALGB Study 9431)
32. Navelbine (NVB)-cisplatin (CDDP) induction chemotherapy (ICT) followed by radiation with or without daily carboplatin (CBDCA) in locally advanced unresectable non small cell lung cancer: Intermediate analysis of a French, multicenter phase III randomised trial
33. Survival benefit from Tirazone (tirapazamine) and cisplatin in advanced non-small cell lung cancer (NSCLC) patients: final results from the international phase III CATAPULT I trial